Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Merck Freezes Cordaptive ACHIEVE Trial

This article was originally published in The Pink Sheet Daily

Executive Summary

Imaging endpoint stalls cholesterol study, per a monitoring panel’s advice.

You may also be interested in...

Merck's Cordaptive: Just Another Cholesterol Combo, or More?

At first glance, Merck's Cordaptive is yet another combination drug for cholesterol. But by unlocking the significant medical benefits of niacin, the treatment may represent an important advance. Cordaptive contains an anti-flushing agent which reduces the key side-effect preventing wider niacin use.

Vytorin Fails To Show ENHANCEd Benefit Over Simvastatin In Plaque Reduction

Merck/Schering-Plough felt pressure to release findings earlier than its scheduled presentation at March American College of Cardiology meeting, Schering-Plough tells “The Pink Sheet” DAILY.

Merck’s Lipid-Lowering Combo Cordaptive Could Clear FDA In Mid-2008

The company announced it has filed the niacin and laropiprant combination, formerly known as MK-0524A.

Related Content





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts